{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"Compared the PFS of interim PET positive participants to the PFS of interim PET negative.","pValue":"0.10","statisticalMethod":"Two-tailed log rank test"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper end of the CI is not estimable because the number of events beyond the median, and their timing, does not permit calculation of the upper confidence interval.","groupId":"OG000","lowerLimit":"0.4","upperLimit":"NA","value":"10.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Interim PET positive participants"},{"categories":[{"measurements":[{"comment":"Median not reached and confidence intervals cannot be reported because of the timing of the events relative to the follow-up of all participants.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Interim PET negative participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"PFS is the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles (each cycle is 21 days + 7 days window) of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival.","dispersionType":"95% Confidence Interval","groups":[{"description":"Combination chemo and biological therapy\n\nRituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5\n\nFilgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle\n\nEtoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles","id":"OG000","title":"Arm 1-Combination Chemo and Biological Therapy"}],"paramType":"MEDIAN","populationDescription":"27 participants had no PET scan.","reportingStatus":"POSTED","timeFrame":"Participants were followed for up to 10.2 years to determine their response on interim PET scans.","title":"Median Interim Positron Emission Tomography (PET) Positive Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"years"}